Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Multiple Dose, Open-Label Study to Assess the Safety and Tolerability of EO2002 Intracameral Injections With or Without Topical Ripasudil in the Treatment of Corneal Edema

NCT05636579 is registered in ClinicalTrials.gov with Asociación para Evitar la Ceguera en México as lead sponsor.

NCT NCT05636579
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05636579 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Multiple Dose, Open-Label Study to Assess the Safety and Tolerability of EO2002 Intracameral Injections With or Without Topical Ripasudil in the Treatment of Corneal Edema
Lead sponsor
Asociación para Evitar la Ceguera en México
Phase
Phase 1
Overall status
Recruiting
Start date
November 8, 2022
Completion date
December 9, 2025
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bullous keratopathy, corneal edema, corneal edema pseudophakic, corneal endothelial dystrophy, endothelial dysfunction, fuchs dystrophy, fuchs' endothelial dystrophy, pseudophakic bullous keratopathy